Neoadjuvant chemotherapy for cervical cancer

Bibliography

• JEMAL A, MURRAY T, SAMUELS A, GHAFOOR A, WARD E, THUN MJ: Cancer statistics, 2003 CA, USA. Cancer J. Clio. (2003) 53:5–26.
   PubMed Web of Science ®Google Scholar
• •The American Cancer Society issues the annual estimates for the number of new cancer cases and deaths expected in the US.
   Google Scholar
• CLINICAL ANNOUNCEMENT: Concurrent chemoradiation for cervical cancer. National Cancer Institute, US Department of Health and Human Services, Public Health Service. National Institutes of Health, Bethesda, MD, USA (February 1999). The National Cancer Institute issued a statement that strong consideration should be given to the incorporation of concurrent cisplatin-based chemotherapy with radiation therapy in women who require radiation therapy for the treatment of cervical cancer.
   Google Scholar
• LAND ONI E MANEO A, COLOMBO Aet al.: Randomised study of radical surgery versus radiotherapy for stage IB-IIA cervical cancer. Lancet (1997) 350:535–540.
   Google Scholar
• •This Phase III trial demonstrated the therapeutic equivalence of surgery versus radiation therapy for Stage I cervical cancer. However, 84% of surgically-treated patients with bulky tumours also required postoperative radiation therapy.
   Google Scholar
• DE WIT R: Overview of bladder trials in the European Organisation for Research and Treatment. European Organisation for Research and Treatment. Cancer (2003) 97:2120–2126.
   Google Scholar
• •Randomised, controlled trials conducted by the EORTC identifed a small 5-year survival advantage with NACT in bladder carcinoma. 865 Expert Op/n. Pharmacother. (2003) 4(6)
   Google Scholar
• URSCHEL JD, VASAN H, BLEWETT CJ: A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for respectable esophageal cancer. Am. j Surg. (2002) 183:274–279.
   PubMed Web of Science ®Google Scholar
• •Surgical respectability and complete surgical respectability are improved with NACT for oesophageal carcinoma.
   Google Scholar
• CRISTOFANILLI M, BUZDAR AU, HORTOBAGYI GN: Update on the management of inflammatory breast cancer. Oncologist (2003) 8:141–148.
   PubMed Web of Science ®Google Scholar
• •NACT is part of the standard multimodality approach to inflammatory breast carcinoma.
   Google Scholar
• FRIEDLANDER ML, ATKINSON K, COPPLESON JVM et al: The integration of chemotherapy into the management of locally advanced cervical cancer: a pilot study. Cynecol Oncol (1984) 19:1–7.
   PubMedGoogle Scholar
• •In this Phase II study, the authors report a 67% response rate to NACT.
   Google Scholar
• PANICI PB, SCAMBIA G, GREGGI S, DI ROBERTO E BAIOCCHI G, MANCUSO S: Neoadjuvant chemotherapy and radical surgery in locally advanced cervical carcinoma: a pilot study. Obstet. Cynecol (1988) 74:344–348.
   Google Scholar
• •In this Phase II study, the authors report a 76% response rate to NACT.
   Google Scholar
• SARDI J, SANANAS C, GIAROLI A, MAYA G, DI PAOLA G: Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri. Cynecol. Oncol (1990) 38:486–493.
   PubMedGoogle Scholar
• •This report suggested that patients treated with NACT prior to surgery had a better outcome compared with a historical control group treated with radiation therapy.
   Google Scholar
• DOTTINO PR, PLAXE SC, BEDDOE AM, JOHNSTON C, COHEN CJ: Induction chemotherapy followed by radical surgery in cervical cancer. Cynecol Oncol. (1991) 40:7–11.
   PubMedGoogle Scholar
• •In this Phase II study the authors report a 100% response rate to NACT.
   Google Scholar
• CHANG HC, LAI CH, CHOU PC et al: Neoadjuvant chemotherapy with cisplatin, vincristine, and bleomycin and radical surgery in early-stage bulky cervican carcinoma. Cancer Chemother. Pharmacol (1992) 30:281–285.
   PubMed Web of Science ®Google Scholar
• •In this Phase II study, the authors report a 85% response rate to NACT.
   Google Scholar
• ZANETTA G, LANDONI F, COLOMBO A, PELLEGRINO A, MANEO A, LEVENTIS C: Three-year results after neoadjuvant chemotherapy, radical surgery, and radiotherapy in locally-advanced cervical carcinoma. Obstet. Cynecol (1993) 82:447–450.
   Google Scholar
• •In this Phase II study, the authors report a 67% response rate to NACT.
   Google Scholar
• BOLTS G, VAN ZAINTEN-PRZYBYSZ I, SCARFONE G et al: Determinants of response to a cisplatin-based regimen as neoadjuvant chemotherapy in stage TB - JIB invasive cervical cancer. Cynecol Oncol (1996) 63:62–65.
   PubMedGoogle Scholar
• •This Phase II study confirms a high response rate to cisplatin-based NACT in cervical cancer Stage IB - JIB.
   Google Scholar
• MINAGAWA Y, KIGAWA J, IRIE T et al: Radical surgery following neoadjuvant chemotherapy for patients with stage IIIB cervical cancer. Ann. Surg. Oncol (1998) 5:539–543.
   PubMedGoogle Scholar
• •Radical hysterectomy was feasible following NACT in two-thirds of patients with Stage IIIB cervical carcinoma.
   Google Scholar
• LAI CH, HSUEH S, CHANG TC etal.: Prognostic factors in patients with bulky stage TB or IIA cervical carcinoma undergoing neoadjuvant chemotherapy and radical hysterectomy. Cynecol Oncol (1997) 64:456–462.
   Google Scholar
• •Clinical response to NACT did not differ according to stage, histological type, tumour size, level of squamous cell carcinoma antigen, or DNA ploidy.
   Google Scholar
• HWANG YY, MOON H, CHO SH et al: Ten-year survival of patients with locally advanced, stage TB-JIB cervical cancer after neoadjuvant chemotherapy and radical hysterectomy. Cynecol Oncol (2001) 82:88–93.
   PubMedGoogle Scholar
• •NACT followed by radical hysterectomy in Stage IB - JIB cervical cancer seemed to improve the long-term survival rate, compared to historical controls.
   Google Scholar
• PANICI PB, GREGGI S, SCAMBIA G etal.: Locally advanced cervical adenocarcinoma: is there a place for chemo-surgical treatment? Cynecol Oncol (1996) 61:44–49.
   Google Scholar
• •This retrospective study provided evidence of the chemosensitivity of locally-advanced cervical adenocarcirtoma and also that chemoresponsiveness is the most potent predictor of cure.
   Google Scholar
• MOORE DH: Contemporary management of squamous cell carcinoma of the cervix. In: Current Problems in Obstetrics, Gynecology and Fertility Mosby Inc., St. Louis, USA (2000) 23:161–190.
   Google Scholar
• •The activity of several new agents for the treatment of advanced/metastatic cervical cancer is discussed in this review article.
   Google Scholar
• MEDEN H, MEIBODI AF, OSMERS R, KRAUSS T, KUHN W: Wertheim's hysterectomy after neoadjuvant carboplatin-based chemotherapy in patients with cervical cancer stage JIB and IIIB. Anti-Cancer Res. (1998) 18:4575–4580.
   PubMedGoogle Scholar
• •NACT with carboplatin/ifosfamide or carboplatin/paclitaxel is well-tolerated and effective in facilitating radical hysterectomy.
   Google Scholar
• ZANETTA G, FEI F, MANGIONI C: Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza. Semin. Oncol (2000) 27\(Suppl. 1):23–27.
   Google Scholar
• •This regimen yields a high response rate with acceptable toxicity but the impact on survival will require a longer follow-up.
   Google Scholar
• GRANIEL CL, REYES M, CHANONA G et al.: Type III radical hysterectomy after induction chemotherapy for patients with locally advanced cervical carcinoma. Int. Cynecol Cancer (2001) 11:210–217.
   PubMedGoogle Scholar
• •Induction chemotherapy with cisplatin/gemcitabine produced a high response rate and did not increase the difficulty of surgery.
   Google Scholar
• SERUR E, MATHEWS RE GATES J, LEVINE P, MAIMAN M, REMY JC: Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix. Cynecol Oncol (997) 65:348–356.
   Google Scholar
• •This underpowered cohort analysis demonstrated a 90% objective response rate to NACT prior to radical hysterectomy without an appreciable improvement in overall survival over surgical treatment alone.
   Google Scholar
• SARDI JE, SANANES CE, GIAROLI AA et al.: Neoadjuvant chemotherapy in cervical carcinoma stage IIB: a randomized controlled trial. Int. j Cynecol Cancer (1998) 8:441–450.
   Web of Science ®Google Scholar
• ••This Phase III trial suggests a survivaladvantage for NACT and radical surgery versus radiation therapy in Stage JIB cervical cancer.
   Google Scholar
• CHANG TC, LATCH, HONG JH etal.: Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage TB and IIA cervical cancer. Oncol. (2000) 18:1740–1747.
   Google Scholar
• ••Despite an 86% objective response rate,NACT did not improve progression-free and overall survival in patients with Stage IB-2 - IIA cervical cancer.
   Google Scholar
• BENEDETTI-PANICI E GREGGI S etal: Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J. Gin Oncol (2001) 20:179–188.
   Google Scholar
• ••This Phase III, Italian, multi-centre studydemonstrated an improvement in progression-free and overall survival with NACT and radical surgery versus radiation therapy.
   Google Scholar
• EDDY GL, MANETTA A, ALVAREZ RD, WILLIAMS L, CREASMAN WT: Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study. Cynecol Oncol (1995) 57:412–416.
   PubMed Web of Science ®Google Scholar
• •This Phase II, GOG study confirmed the activity and feasibility of cisplatin plus vincristine NACT in a multi-institutional setting.
   Google Scholar
• SOUHAMI L, GIL RA, ALLAN SE et al: A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. J. Gun. Oncol (1991) 9:970–977.
   Google Scholar
• ••This Phase III trial suggests inferior resultswhen NACT is administered prior to radiation therapy in patients with locally-advanced cervical cancer.
   Google Scholar
• TATTERSALL MHN, LORVIDHAYA V et al.: Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Gun. Omni (1995) 13:444–451.
   Google Scholar
• ••This Phase III trial suggests inferior resultswhen NACT is administered prior to radiation therapy in patients with locally-advanced cervical cancer.
   Google Scholar
• CHIARA S, BRUZZONE M, MERLINI L etal.: Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma. Am. J. Cirri Omni (1994) 17:294–297.
   Google Scholar
• ••This Phase III trial suggests inferiorresults when NACT is administered prior to radiation therapy in patients with locally-advanced cervical cancer.
   Google Scholar
• SARDI JE, GIAROLI A, SANANES C et al.: Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage IB squamous carcinoma of the cervix. The final results. Cynecol Omni (1997) 67:61–69.
   PubMed Web of Science ®Google Scholar
• ••There was improved survival for patientswith bulky cervical tumours treated with NACT followed by radical hysterectomy and radiation therapy, compared to standard therapy.
   Google Scholar
• CHAUVERGNE J, ROHART J, HERON JF etal.: Randomized Phase III trial of neo-adjuvant chemotherapy plus radiotherapy in stage IIB, III carcinoma of the cervix: a cooperative study of the French Oncology Centers. Proc. Ann. Soc. Gin Omni (1988) 7:136 (Abstract 524).
   Google Scholar
• •There was no difference in outcome for patients treated with NACT and radiation therapy versus radiation therapy alone.
   Google Scholar
• SUNDFOR K, TROPE CG, HOGBERG T etal.: Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A. Cancer (1996) 77:2371–2378.
   Google Scholar
• •There was no difference in outcome for patients treated with NACT and radiation therapy versus radiation therapy alone.
   Google Scholar
• LEBORGNE E LEBORGNE JH, DOLDAN R et al: Induction chemotherapy and radiotherapy of advanced cancer of the cervix: a pilot study and Phase III randomized trial. Int. j Radiat. Oncol Biol. Phys. (1997) 37:343–350.
   PubMedGoogle Scholar
• •There was no difference in the outcome of patients treated with NACT and radiation therapy, versus radiation therapy alone.
   Google Scholar
• KUMAR L, GROVER R, POKHAREL YH et al.: Neoadjuvant chemotherapy in locally advanced cervical cancer: two randomised studies. Aust. NZ J. Med. (1998) 28:387–390.
   PubMedGoogle Scholar
• •There was no difference in outcome of patients treated with NACT and radiation therapy, versus radiation therapy alone.
   Google Scholar
• SYMONDS RE HABESHAW T, REED NS et al: The Scottish and Manchester randomised trial of neoadjuvant chemotherapy for advanced cervical cancer. Eur. J. Cancer (2000) 36:994–1001.
   PubMedGoogle Scholar
• •There was no difference in outcome of patients treated with NACT and radiation therapy, versus radiation therapy alone.
   Google Scholar
• HEROD J, BURTON A, BUXTON J et al: A randomised prospective Phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versus radiotherapy alone in inoperable cancer of the cervix. Ann. Oncol. (2000) 11:1175–1181.
   PubMed Web of Science ®Google Scholar
• •There was no difference in outcome of patients treated with NACT and radiation therapy, versus radiation therapy alone.
   Google Scholar
• TIERNEY JF, STEWART LA, PARMAR MKB: Can the published data tell us about the effectiveness of neoadjuvant chemotherapy for locally advanced cancer of the uterine cervix? Eur. J. Cancer (1999) 35:406-409. Meta-analyses of the published data at 2 and 3 years are not clearly in favour of NACT or control treatment.
   Google Scholar
• MORRIS M, EIFEL PJ, LU J et al: Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high-risk cervical cancer: a randomized Radiation Therapy Oncology Group clinical trial. N Engl. J. Med. (1999) 340:1137–1143.
   PubMed Web of Science ®Google Scholar
• ••This Phase III trial conducted by theRTOG, confirmed the superiority of pelvic radiation therapy with concurrent cisplatin plus 5-fluorouracil chemotherapy over extended-field radiation therapy in patients with Stage IB-2 - WA cervical carcinoma.
   Google Scholar
• PETERS WA, LIU PY, BARRETT RJ etal.: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Gin Omni (2000) 18:1606–1613.
   Google Scholar
• ••This Phase III trial conducted by theRTOG confirmed the superiority of pelvic radiation therapy with concurrent cisplatin plus 5-fluorouracil chemotherapy over pelvic radiation therapy alone in patients with high risk factors for recurrence following primary radical hysterectomy.
   Google Scholar
• KEYS HM, BUNDY BN, STEHMAN FB eta].: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl. J. Med. (1999) 340:1154–1161.
   Google Scholar
• ••This Phase III trial conducted by the GOGconfirmed the superiority of radiation therapy plus weekly cisplatin chemotherapy versus radiation therapy alone, prior to extrafascial hysterectomy, in patients with bulky Stage IB-2 cervical carcinoma. Expert Op/n. Pharmacother. (2003) 4(6)
   Google Scholar